Deferiprone Treatment in Aged Transgenic Tau Mice Improves Y-Maze Performance and Alters Tau Pathology

Overview

Journal Neurotherapeutics

Specialty Neurology

Date 2021 Jan 7

PMID 33410108

Citations 9

Authors

Shalini S Rao

Larissa Lago

Irene Volitakis

Jay J Shukla

Gawain McColl

David I Finkelstein

Paul A Adlard

Affiliations

Soon will be listed here.

Abstract

The accumulation of neurofibrillary tangles (NFTs), which is composed of abnormally hyperphosphorylated tau aggregates, is the classic neuropathology associated with cognitive dysfunction in tauopathies such as Alzheimer's disease (AD). However, there is an emerging theory suggesting that dysregulation in cerebral iron may contribute to NFT formation. Iron is speculated to bind to tau and induce conformational changes of the protein, potentially leading to subsequent aggregation and cognitive decline. Deferiprone (DFP) is a clinically available iron chelator, which has demonstrated potential therapeutic advantages of chelating iron in neurodegenerative disorders, and is currently in clinical trials for AD. However, its effect on tau pathology remains unclear. Here, we report the effects of short-term DFP treatment (4 weeks, 100 mg/kg/daily, via oral gavage) in a mixed-gender cohort of the rTg4510 mouse model of tauopathy. Our results revealed that DFP improved Y-maze and open field performance, accompanied by a 28% decrease in brain iron levels, measured by inductively coupled plasma mass spectrometry (ICP-MS) and reduced AT8-labeled p-tau within the hippocampus in transgenic tau mice. This data supports the notion that iron may play a neurotoxic role in tauopathies and may be a potential therapeutic target for this class of disorders that can be modulated by the clinically available metal chelator DFP.

Citing Articles

Let-7b-TLR7 Signaling Axis Contributes to the Anesthesia/Surgery-Induced Cognitive Impairment.

Deng L, Gao R, Chen H, Jiao B, Zhang C, Wei L Mol Neurobiol. 2023; 61(3):1818-1832.

PMID: 37782443 DOI: 10.1007/s12035-023-03658-4.

Iron-overload-induced ferroptosis in mouse cerebral toxoplasmosis promotes brain injury and could be inhibited by Deferiprone.

Wang C, Xie L, Xing Y, Liu M, Yang J, Gao N PLoS Negl Trop Dis. 2023; 17(8):e0011607.

PMID: 37651502 PMC: 10508604. DOI: 10.1371/journal.pntd.0011607.

Iron homeostasis imbalance and ferroptosis in brain diseases.

Long H, Zhu W, Wei L, Zhao J MedComm (2020). 2023; 4(4):e298.

PMID: 37377861 PMC: 10292684. DOI: 10.1002/mco2.298.

COVID-19-induced neurological symptoms: focus on the role of metal ions.

Zhang Y, Ren K, Luo X, Peng J Inflammopharmacology. 2023; 31(2):611-631.

PMID: 36892679 PMC: 9996599. DOI: 10.1007/s10787-023-01176-2.

Modulatory Role of Curcumin on Cobalt-Induced Memory Deficit, Hippocampal Oxidative Damage, Astrocytosis, and Nrf2 Expression.

Oria R, Anyanwu G, Esom E, Nto J, Katchy A, Agu A Neurotox Res. 2023; 41(3):201-211.

PMID: 36692684 DOI: 10.1007/s12640-023-00635-6.

References

Lovell M, Xiong S, Xie C, Davies P, Markesbery W . Induction of hyperphosphorylated tau in primary rat cortical neuron cultures mediated by oxidative stress and glycogen synthase kinase-3. J Alzheimers Dis. 2005; 6(6):659-71. DOI: 10.3233/jad-2004-6610. View

van Duijn S, Bulk M, van Duinen S, Nabuurs R, van Buchem M, van der Weerd L . Cortical Iron Reflects Severity of Alzheimer's Disease. J Alzheimers Dis. 2017; 60(4):1533-1545. PMC: 5676973. DOI: 10.3233/JAD-161143. View

Carboni E, Tatenhorst L, Tonges L, Barski E, Dambeck V, Bahr M . Deferiprone Rescues Behavioral Deficits Induced by Mild Iron Exposure in a Mouse Model of Alpha-Synuclein Aggregation. Neuromolecular Med. 2017; 19(2-3):309-321. PMC: 5570801. DOI: 10.1007/s12017-017-8447-9. View

Treit D, Fundytus M . Thigmotaxis as a test for anxiolytic activity in rats. Pharmacol Biochem Behav. 1988; 31(4):959-62. DOI: 10.1016/0091-3057(88)90413-3. View

Nunez M, Urrutia P, Mena N, Aguirre P, Tapia V, Salazar J . Iron toxicity in neurodegeneration. Biometals. 2012; 25(4):761-76. DOI: 10.1007/s10534-012-9523-0. View

Daugherty A, Raz N . Appraising the Role of Iron in Brain Aging and Cognition: Promises and Limitations of MRI Methods. Neuropsychol Rev. 2015; 25(3):272-87. PMC: 4565753. DOI: 10.1007/s11065-015-9292-y. View

Huber C, Yee C, May T, Dhanala A, Mitchell C . Cognitive Decline in Preclinical Alzheimer's Disease: Amyloid-Beta versus Tauopathy. J Alzheimers Dis. 2017; 61(1):265-281. PMC: 5734131. DOI: 10.3233/JAD-170490. View

Sengupta A, Kabat J, Novak M, Wu Q, Grundke-Iqbal I, Iqbal K . Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Arch Biochem Biophys. 1998; 357(2):299-309. DOI: 10.1006/abbi.1998.0813. View

Louis J, Martens E, Borghgraef P, Lambrecht C, Sents W, Longin S . Mice lacking phosphatase PP2A subunit PR61/B'delta (Ppp2r5d) develop spatially restricted tauopathy by deregulation of CDK5 and GSK3beta. Proc Natl Acad Sci U S A. 2011; 108(17):6957-62. PMC: 3084077. DOI: 10.1073/pnas.1018777108. View

10.

Simon P, Dupuis R, Costentin J . Thigmotaxis as an index of anxiety in mice. Influence of dopaminergic transmissions. Behav Brain Res. 1994; 61(1):59-64. DOI: 10.1016/0166-4328(94)90008-6. View

11.

Lei P, Ayton S, Moon S, Zhang Q, Volitakis I, Finkelstein D . Motor and cognitive deficits in aged tau knockout mice in two background strains. Mol Neurodegener. 2014; 9:29. PMC: 4141346. DOI: 10.1186/1750-1326-9-29. View

12.

Noble W, Olm V, Takata K, Casey E, Mary O, Meyerson J . Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron. 2003; 38(4):555-65. DOI: 10.1016/s0896-6273(03)00259-9. View

13.

Rammes G, Steckler T, Kresse A, Schutz G, Zieglgansberger W, Lutz B . Synaptic plasticity in the basolateral amygdala in transgenic mice expressing dominant-negative cAMP response element-binding protein (CREB) in forebrain. Eur J Neurosci. 2000; 12(7):2534-46. DOI: 10.1046/j.1460-9568.2000.00108.x. View

14.

SantaCruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M . Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005; 309(5733):476-81. PMC: 1574647. DOI: 10.1126/science.1113694. View

15.

Michalon A, Koshibu K, Baumgartel K, Spirig D, Mansuy I . Inducible and neuron-specific gene expression in the adult mouse brain with the rtTA2S-M2 system. Genesis. 2005; 43(4):205-12. DOI: 10.1002/gene.20175. View

16.

Lowe V, Wiste H, Senjem M, Weigand S, Therneau T, Boeve B . Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. Brain. 2017; 141(1):271-287. PMC: 5837250. DOI: 10.1093/brain/awx320. View

17.

Bulk M, Kenkhuis B, van der Graaf L, Goeman J, Natte R, van der Weerd L . Postmortem T2*- Weighted MRI Imaging of Cortical Iron Reflects Severity of Alzheimer's Disease. J Alzheimers Dis. 2018; 65(4):1125-1137. PMC: 6218127. DOI: 10.3233/JAD-180317. View

18.

Lei P, Ayton S, Finkelstein D, Spoerri L, Ciccotosto G, Wright D . Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat Med. 2012; 18(2):291-5. DOI: 10.1038/nm.2613. View

19.

Guo C, Wang P, Zhong M, Wang T, Huang X, Li J . Deferoxamine inhibits iron induced hippocampal tau phosphorylation in the Alzheimer transgenic mouse brain. Neurochem Int. 2012; 62(2):165-72. DOI: 10.1016/j.neuint.2012.12.005. View

20.

Munoz P, Zavala G, Castillo K, Aguirre P, Hidalgo C, Nunez M . Effect of iron on the activation of the MAPK/ERK pathway in PC12 neuroblastoma cells. Biol Res. 2006; 39(1):189-90. DOI: 10.4067/s0716-97602006000100021. View